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Abstract
Single nucleotide polymorphisms (SNPs) in MYH9 and APOL1 on chromosome 22 (c22) are powerfully associated with non-
diabetic end-stage renal disease (ESRD) in African Americans (AAs). Many AAs diagnosed with type 2 diabetic nephropathy
(T2DN) have non-diabetic kidney disease, potentially masking detection of DN genes. Therefore, genome-wide association
analyses were performed using the Affymetrix SNP Array 6.0 in 966 AA with T2DN and 1,032 non-diabetic, non-nephropathy
(NDNN) controls, with and without adjustment for c22 nephropathy risk variants. No associations were seen between
FRMD3 SNPs and T2DN before adjusting for c22 variants. However, logistic regression analysis revealed seven FRMD3 SNPs
significantly interacting with MYH9—a finding replicated in 640 additional AA T2DN cases and 683 NDNN controls.
Contrasting all 1,592 T2DN cases with all 1,671 NDNN controls, FRMD3 SNPs appeared to interact with the MYH9 E1
haplotype (e.g., rs942280 interaction p-value=9.3E
27 additive; odds ratio [OR] 0.67). FRMD3 alleles were associated with
increased risk of T2DN only in subjects lacking two MYH9 E1 risk haplotypes (rs942280 OR=1.28), not in MYH9 E1 risk allele
homozygotes (rs942280 OR=0.80; homogeneity p-value=4.3E
24). Effects were weaker stratifying on APOL1. FRMD3 SNPS
were associated with T2DN, not type 2 diabetes per se, comparing AAs with T2DN to those with diabetes lacking
nephropathy. T2DN-associated FRMD3 SNPs were detectable in AAs only after accounting for MYH9, with differential effects
for APOL1. These analyses reveal a role for FRMD3 in AA T2DN susceptibility and accounting for c22 nephropathy risk
variants can assist in detecting DN susceptibility genes.
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Introduction
Impressive genetic association is observed between single
nucleotide polymorphisms (SNPs) on chromosome 22q (c22)
and a spectrum of related kidney disorders [1–9]. Nearly 40% of
end-stage renal disease (ESRD) in African Americans (AAs) may
be attributable to c22 nephropathy risk variants, including 70%
of non-diabetic ESRD [10]. Fine mapping studies reveal that
several independent SNPs and regions in and near the
apolipoprotein L1 gene (APOL1) and non-muscle myosin heavy
chain 9 gene (MYH9) are associated with nephropathy suscep-
tibility [11]. The strongest associations are observed with focal
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Virus-associated nephropathy (HIVAN or HIV-associated col-
lapsing glomerulopathy), and hypertension-attributed ESRD
(HA-ESRD or focal global glomerulosclerosis [FGGS]). Odds
ratios (OR) for the APOL1 G1 (non-synonymous coding variant
342G:384M) and G2 (6 basepair deletion) range from 10.5 in
FSGS to 7.3 in non-diabetic HA-ESRD. In the case of MYH9,E 1
risk haplotype ORs range from 5–8 in FSGS to 2–3.4 in non-
diabetic ESRD. Although the nephropathy association with
MYH9 is markedly attenuated after accounting for the coding
variants in APOL1, three groups observe independent MYH9
association with non-diabetic nephropathy (personal communi-
cation 2010: Jeffrey Kopp; Carl Langefeld; Linda Kao). Weaker
associations were reported between MYH9 and type 2 diabetes-
(T2DM) associated ESRD in AA (OR,1.4) [4]. One explanation
is that a subset of patients thought to have diabetic nephropathy
(DN) had FSGS with coincident T2DM. We reported such a case
[12] and estimate that this subset approaches 12–16% of AA with
clinically diagnosed DN [4].
Approximately 12% of AAs carry two APOL1 risk variants and
are at risk for FSGS and ,50% with HIV infection will develop
HIVAN in the absence of anti-retroviral therapy. Thus, additional
modifying environmental and/or inherited factors appear neces-
sary to initiate kidney disease [13,14]. Since HIV infection
increases the risk for nephropathy by a factor of nearly fivefold, it
is possible that other environmental or genetic factors interact with
APOL1 and/or MYH9 to mediate risk of renal disease. Gene-gene
interactions are a likely contributor to susceptibility for diabetic
and non-diabetic nephropathy and were the focus of these
analyses.
A genome-wide association study (GWAS) using the Affymetrix
Genome Wide Human 6.0 SNP chip was completed to identify
genetic polymorphisms that mediate risk for T2DM-ESRD in AA
[15]. Herein, we scanned the genome to detect polymorphisms
mediating risk for T2DM-ESRD, conditional on APOL1 G1/G2
nephropathy risk variants and the MYH9 E1 risk haplotype using
case-control and case-only study designs. The case-only design
increases the statistical power over more classic case-control
designs, allowing us to maximize power for the first genome-wide
scan testing for interactions with the strongest genetic risk factor
for ESRD. We tested for replication in additional AA cases with
T2DM-ESRD and AA controls with T2DM lacking nephropathy.
Together, these study designs have the potential to detect
additional genes mediating the risk for T2DM-ESRD in AAs,
accounting for the effects of non-diabetic etiologies of nephropathy
with evidence for association on c22. We were also able to assess
whether the adjacent APOL1 and MYH9 genes exhibited similar
effects.
Results
The discovery GWAS association analysis included 952 AA
cases with T2DM-ESRD and 988 AA non-diabetic, non-
nephropathy controls, as published [15]. Principal component
(PC) analysis identified one PC that controlled for global
admixture in this sample and yielded an inflation factor of 1.01
(see Table S1 and Figure S1). Replication analyses were performed
in 640 additional unrelated T2DM-ESRD cases and 683 non-
diabetic, non-nephropathy controls recruited using identical
criteria. Finally, an additional 513 AA with T2DM lacking
nephropathy were subsequently evaluated to determine whether
associations observed between T2DM-ESRD cases and non-
diabetic, non-nephropathy controls reflected nephropathy suscep-
tibility or risk of T2DM per se. Table 1 displays the numbers in
each case and control group that were homozygous for MYH9 E1
risk haplotypes and had 2 APOL1 G1 and/or G2 nephropathy risk
variants, along with demographic characteristics. Individuals with
the MYH9 E1 haplotype or APOL1 risk variants (homozygous or
heterozygous) tended to have greater estimated West African
ancestry based on the principal component analysis (PCA) (p-
value,1E
24).
Examination of the top 100 SNP interactions with c22 risk
variants (Table S2) identified SNPs within two previously
reported nephropathy susceptibility genes, FRMD3 and
SHROOM3 [16,17]. These genes were further evaluated. Results
of the case-only analysis in the T2DM-ESRD discovery samples
revealed that 7 SNPs in FRMD3 appeared to interact with the
MYH9 E1 haplotype (Table 2), as did 2 SNPs in SHROOM3,
rs1493360 and rs17002201 (data not shown). SHROOM3 SNPs
failed replication and were not further investigated. The
FRMD3 effects were in the same direction in case-only, case-
control and MYH9 E1 haplotype stratified case-control analyses.
These SNPs in FRMD3 were all in high linkage disequilibrium
(LD; Yoruban r
2=0.95–1.0; CEU r
2=1.0) and appeared to
confer protective effects against T2DM-ESRD in MYH9-E1 risk
homozygotes, despite having significant risk effects in non-E1
homozygotes. This effect w a sl e s sp r o n o u n c e df o rAPOL1.
Importantly, there was no evidence of association of FRMD3 or
any of the other top 100 SNPs with T2DM-ESRD in the
original GWAS, prior to accounting for these c22 nephropathy
risk variants [15].
Table 3 contains the replication analysis results in T2DM-
ESRD cases and non-diabetic, non-nephropathy controls with 5 of
the 7 FRMD3 SNPs that could easily be multiplexed. The
apparent interactive relationship between MYH9 and FRMD3
SNPs was maintained despite the smaller sample. Weaker effects
persisted for APOL1. A combined analysis was then performed
using all 1,592 T2DM-ESRD discovery and replication cases
relative to all 1,671 non-diabetic, non-nephropathy controls
(Table 4). Analyses in T2DM-ESRD cases suggested significant
Author Summary
African Americans have high rates of kidney disease
attributed to type 2 diabetes mellitus. However, approx-
imately 25% of patients are misclassified and have non-
diabetic kidney disease on renal biopsy. The APOL1-MYH9
gene region on chromosome 22 is powerfully associated
with non-diabetic kidney diseases in African Americans.
Therefore, we tested for interactions between single
nucleotide polymorphisms across the genome with APOL1
and MYH9 non-diabetic nephropathy risk variants in
African Americans with presumed diabetic nephropathy.
Markers in FRMD3, a gene associated with type 1 diabetic
nephropathy in Caucasians, appeared to interact with
MYH9; however, increased nephropathy risk was seen in
diabetic cases lacking two MYH9 risk haplotypes, and
protective effects were seen in those with two MYH9 risk
haplotypes. Stratified analyses based on the chromosome
22 nephropathy risk haplotypes demonstrated that FRMD3
variants were associated with diabetic nephropathy risk in
cases without two MYH9 (or APOL1) risk haplotypes. It
appears that African Americans with diabetes and kidney
disease who are not chromosome 22 nephropathy risk
variant homozygotes are enriched for the presence of
diabetic nephropathy and FRMD3 risk alleles. This genetic
dissection ultimately allowed for detection of the FRMD3
diabetic nephropathy gene association in a subset of cases
enriched for this disorder.
FRMD3 and Diabetic Nephropathy
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p=9.28E
27 additive; OR 0.67, 95% CI 0.57–0.78). Subsequent
analyses revealed that FRMD3 SNP rs942280 (and others) were
significantly associated with increased risk for T2DM-ESRD in
non-MYH9 E1 risk haplotype homozygotes (rs942280 OR 1.28,
95% CI 1.09–1.51), but not in MYH9 E1 risk allele homozygotes
(homozygosity p-value comparing the effect of FRMD3 SNPs in
MYH9 E1 non-risk homozygotes vs. MYH9 E1 risk homozygo-
tes=4.82E
24). Therefore, the major effect of risk from FRMD3 on
T2DM-ESRD susceptibility was present in non-MYH9 E1
haplotype homozygotes. Although the direction of effect was the
same when replacing the MYH9 E1 haplotype with APOL1 risk
variants, results were less significant. This could have resulted from
the smaller number of APOL1 risk homozygotes.
To determine whether the FRMD3 SNPs were associated with
susceptibility to T2DM-ESRD or diabetes per se, a final analysis
was performed. FRMD3 allele frequencies were compared
between the 513 unrelated AAs with T2DM lacking nephropathy
and the 1,592 T2DM-ESRD cases (Table 5). This revealed
significant differences in 3 SNP frequencies comparing T2DM-
ESRD non-E1 haplotype homozygote cases to controls with
T2DM lacking nephropathy (single SNP OR in non-E1
homozygotes and p-value: rs942278 OR 1.26 p=0.0241;
rs942280 OR 1.22 p=4.73E
22; rs1535753 OR 1.21
p=5.48E
22; rs942283 OR 1.18 p=9.58E
22; rs23786558 OR
1.18 p=9.66E
22). These differences were not detectable in non-
MYH9 E1 stratified analyses (data not shown). In addition,
FRMD3 allele frequencies in the 513 AA with T2DM lacking
Table 1. Demographic characteristics of study groups.
Sample (N) Analysis
MYH9, APOL1
Risk (N)* Age (years)
Sex (%
female) BMI (kg/m
2) Admixture %
Dialysis
Duration
(years)
T2DM Duration
(years)
T2DM-ESRD (952) Discovery 365, 200 61.65610.65 61.04 29.6867.84 0.8060.11 3.6564.04 19.80610.63
Non-T2DM Control
(988)
Discovery 308, 110 48.98611.98 57.17 30.0867.84 0.7860.11 N/A N/A
T2DM-ESRD (640) Replication 262, 134 60.14610.16 57.16 missing 0.8060.11 3.2563.78 20.72610.73
Non-T2DM Control
(683)
Replication 244, 108 48.54612.56 51.62 missing 0.7760.11 N/A N/A
T2DM Non-
Nephropathy (513)
Phenotype
Clarification
170, 57 56.84611.47 65.63 33.4267.34 0.7660.12 N/A 10.3868.99
a
ACR – urine albumin:creatinine ratio; N/A not applicable; a – median 8.0; b – median 3.0; c – median 0.9;
*denotes number with two MYH9 E1 risk haplotypes or two APOL1 G1 and/or G2 nephropathy risk variants.
doi:10.1371/journal.pgen.1002150.t001
Table 2. Discovery sample chromosome 22-FRMD3 interaction analysis.
T2DM-ESRD
Case Only Analysis
NDNN Control
OnlyAnalysis
Cases vs.
Controls
c22 risk
homozygotes
Non-c22 risk
homozygotes
c22 risk
homozygotes
vs.
non-risk
Marker
Gene
Interaction
P-Value
Additive OR (95% CI)
P-Value
Additive OR (95% CI)
Homogeneity
P-Value OR (95% CI) OR (95% CI)
Homogeneity
P-Value*
Classic
Logit
P-
Value**
rs2378658 MYH9 6.4E-4 0.70 (0.57,0.86) 6.3E-1 1.06 (0.84, 1.33) 7.4E-3 0.81 (0.61,1.07) 1.27 (1.03,1.56) 1.2E-2 1.4E-2
APOL1 4.3E-2 0.77 (0.6,0.99) 4.0E-1 1.14 (0.84,1.54) 2.1E-2 0.68 (0.45,1.04) 1.13 (0.94,1.37) 3.1E-2 2.9E-2
rs1535753 MYH9 5.6E-4 0.69 (0.56,0.85) 5.9E-1 1.07 (0.85, 1.34) 5.9E-3 0.79 (0.60,1.05) 1.27 (1.03,1.57) 8.1E-3 9.5E-3
APOL1 5.4E-2 0.79 (0.61,1.0) 3.3E-1 1.16 (0.86,1.56) 1.9E-2 0.67 (0.44,1.01) 1.13 (0.94,1.37) 2.4E-2 2.2E-2
rs1535752 MYH9 4.6E-4 0.69 (0.56,0.85) 6.3E-1 1.06 (0.84, 1.33) 6.1E-3 0.80 (0.6,1.06) 1.28 (1.04,1.57) 9.2E-3 1.1E-2
APOL1 Not tested - - -
rs942283 MYH9 2.5E-4 0.68 (0.55,0.83) 5.5E-1 1.07 (0.85, 1.35) 3.3E-3 0.77 (0.58,1.03) 1.28 (1.04,1.58) 4.7E-3 5.5E-3
APOL1 7.1E-2 0.8 (0.62,1.02) 2.6E-1 1.19 (0.88,1.6) 1.5E-2 0.66 (0.43,0.99) 1.12 (0.93,1.36) 2.1E-2 1.9E-2
rs942280 MYH9 1.5E-4 0.67 (0.54,0.82) 4.2E-1 1.1 (0.87, 1.38) 1.5E-3 0.75 (0.57,1.00) 1.34 (1.09,1.65) 1.2E-3 1.4E-3
APOL1 2.2E-2 0.75 (0.59,0.96) 2.6E-1 1.19 (0.88,1.6) 5.3E-3 0.60 (0.4,0.92) 1.17 (0.97,1.41) 5.0E-3 4.1E-3
rs942278 MYH9 2.6E-4 0.68 (0.55,0.84) 3.7E-1 1.11 (0.88, 1.4) 1.6E-3 0.80 (0.60,1.06) 1.35 (1.09,1.66) 3.1E-3 3.7E-3
APOL1 7.0E-2 0.8 (0.62,1.02) 2.8E-1 1.18 (0.87,1.59) 8.9E-3 0.67 (0.45,1.02) 1.18 (0.97,1.42) 1.7E-2 1.58E-2
rs10867977 MYH9 1.4E-4 0.67 (0.54,0.82) 7.1E-1 1.04 (0.83, 1.32) 4.1E-3 0.85 (0.64,1.12) 1.32 (1.07,1.63) 1.4E-2 1.7E-2
APOL1 Not tested - - -
952 T2DM-ESRD cases versus 988 non-T2DM, non-nephropathy (NDNN) controls (* Homogeneity P-Value refers to the P-Value from the test for homogeneity of the
odds ratio; ** Two-locus logistic regression interaction analysis).
doi:10.1371/journal.pgen.1002150.t002
FRMD3 and Diabetic Nephropathy
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1,671 non-diabetic, non-nephropathy controls, whether or not
stratified on MYH9 E1 haplotype homozygosity (all p-
values.6E
21). In addition, significant interactions for MYH9
were not observed with these 5 FRMD3 SNPs in an independent
NIH series of 283 biopsy-proven FSGS and HIVAN cases vs. 222
non-nephropathy controls, suggesting the effects are limited to
T2DM-ESRD (data not shown). Tables S3 and S4 contain
FRMD3 allele frequencies, based on numbers of MYH9 E1 or
APOL1 risk haplotypes, respectively.
Discussion
Herein we report association analysis results accounting for the
effects of APOL1 and MYH9 on risk of DN in AAs. Stratified and
interaction analyses performed in cases with T2DM-ESRD
provided an unbiased assessment of potential interactions between
both the APOL1 G1/G2 risk variants and MYH9 E1 risk haplotype
with nearly one million SNPs across the genome. MYH9 and
APOL1 are strongly associated with non-diabetic ESRD in AAs
and can potentially limit ability to detect other nephropathy
Table 3. Replication sample chromosome 22-FRMD3 interaction analysis.
T2DM-ESRD
Cases Only
NDNN Controls
Only
Cases vs.
Controls
c22 risk
homozygotes
non-c22 risk
homozygotes
c22 risk
homozygotes vs.
non-risk
Marker
Gene
Interaction
P-Value
Additive OR (95% CI)
P-Value
Additive OR (95% CI)
Homogeneity
P-Value OR (95% CI) OR (95% CI)
Homogeneity
P-Value*
Classic
Logit
P-
Value**
rs2378658 MYH9 3.7E-3 0.68 (0.52,0.88) 6.8E-1 0.95 (0.73,1.23) 1.5E-1 0.87 (0.63,1.21) 1.23 (0.96,1.58) 9.7E-2 1.0E-1
APOL1 3.6E-2 0.70 (0.50,0.98) 5.2E-1 1.12 (0.79,1.58) 5.1E-2 0.79 (0.51,1.24) 1.14 (0.91,1.43) 1.6E-1 3.4E-1
rs1535753 MYH9 7.7E-3 0.70 (0.54,0.91) 7.8E-1 0.96 (0.74,1.25) 1.7E-1 0.84 (0.61,1.17) 1.20 (0.93,1.55) 8.6E-2 8.7E-2
APOL1 4.0E-2 0.71 (0.51,0.98) 4.7E-1 1.14 (0.80,1.61) 4.8E-2 0.77 (0.49,1.21) 1.12 (0.89,1.40) 1.5E-1 2.7E-1
rs942283 MYH9 2.1E-3 0.66 (0.51,0.86) 6.2E-1 0.94 (0.72,1.21) 1.4E-1 0.85 (0.61,1.18) 1.22 (0.95,1.58) 8.0E-2 8.2E-2
APOL1 1.9E-2 0.67 (0.48,0.94) 6.6E-1 1.08 (0.76,1.53) 4.8E-2 0.77 (0.49,1.2) 1.12 (0.90,1.41) 1.4E-1 3.3E-1
rs942280 MYH9 1.4E-3 0.65 (0.50,0.85) 5.2E-1 0.92 (0.71,1.19) 1.6E-1 0.87 (0.63,1.21) 1.22 (0.95,1.57) 1.1E-1 1.1E-1
APOL1 3.3E-2 0.70 (0.50,0.97) 6.2E-1 1.09 (0.77,1.54) 6.0E-2 0.82 (0.53,1.27) 1.13 (0.90,1.41) 2.1E-1 3.4E-1
rs942278 MYH9 1.5E-2 0.72 (0.56,0.94) 5.5E-1 0.92 (0.71,1.20) 3.2E-1 0.94 (0.68,1.30) 1.26 (0.98,1.62) 1.6E-1 1.7E-1
APOL1 5.8E-2 0.73 (0.52,1.01) 6.3E-1 1.09 (0.77,1.54) 9.0E-2 0.86 (0.55,1.35) 1.18 (0.94,1.48) 2.4E-1 4.0E-1
640 T2DM-ESRD cases versus 683 non-T2DM, non-nephropathy (NDNN) controls (* Homogeneity P-Value refers to the P-Value from the test for homogeneity of the
odds ratio; ** Two-locus logistic regression interaction analysis).
doi:10.1371/journal.pgen.1002150.t003
Table 4. Combined chromosome 22-FRMD3 interaction analysis.
T2DM-ESRD
Cases Only
NDNN Controls
Only
Cases vs.
Controls
c22-risk
homozygotes
non-c22 risk
homozygotes
c22 risk homozygotes
vs. non-risk
Marker
Gene
Interaction
P-Value
Additive OR (95% CI)
P-Value
Additive OR (95% CI)
Homogeneity
P-Value OR (95% CI) OR (95% CI)
Homogeneity
P-Value*
Classic
Logit
P-
Value**
rs2378658 MYH9 9.5E-6 0.69 (0.59,0.82) 9.2E-1 1.01 (0.85,1.20) 5.7E-3 0.83 (0.67,1.03) 1.25 (1.06,1.46) 2.9E-3 4.0E-3
APOL1 4.5E-3 0.75 (0.61,0.91) 1.9E-1 1.17 (0.93,1.49) 3.6E-3 0.74 (0.55,1.0) 1.13 (0.98,1.31) 1.3E-2 2.6E-2
rs1535753 MYH9 1.7E-5 0.70 (0.60,0.82) 8.2E-1 1.02 (0.86,1.21) 5.3E-3 0.81 (0.66,1.01) 1.24 (1.06,1.46) 1.8E-3 2.4E-3
APOL1 6.0E-3 0.76 (0.62,0.92) 1.4E-1 1.20 (0.94,1.52) 3.1E-3 0.72 (0.53,0.98) 1.12 (0.97,1.29) 1.0E-2 1.6E-2
rs1535752 MYH9 5.0E-4 0.69 (0.56,0.85) 6.1E-1 1.06 (0.84,1.34) 1.2E-2 0.80 (0.61,1.07) 1.27 (1.03,1.57) 1.1E-2 1.3E-2
rs942283 MYH9 2.3E-6 0.68 (0.57,0.79) 8.7E-1 1.01 (0.85,1.20) 2.8E-3 0.80 (0.65,0.99) 1.25 (1.07,1.47) 1.0E-3 1.4E-3
APOL1 3.6E-3 0.74 (0.61,0.91) 1.7E-1 1.18 (0.93,1.5) 2.9E-3 0.72 (0.53,0.97) 1.12 (0.97,1.29) 9.8E-3 1.9E-2
rs942280 MYH9 9.3E-7 0.67 (0.57,0.78) 8.1E-1 1.02 (0.86,1.21) 1.6E-3 0.80 (0.65,0.99) 1.28 (1.09,1.51) 4.8E-4 7.0E-4
APOL1 1.2E-3 0.72 (0.59,0.88) 1.6E-1 1.18 (0.93,1.5) 1.3E-3 0.71 (0.52,0.95) 1.15 (0.99,1.33) 4.4E-3 6.7E-3
rs942278 MYH9 1.5E-5 0.70 (0.59,0.82) 7.7E-1 1.03 (0.86,1.22) 4.2E-3 0.85 (0.69,1.06) 1.30 (1.11,1.53) 1.6E-3 2.3E-3
APOL1 6.5E-3 0.76 (0.62,0.93) 1.3E-1 1.20 (0.95,1.52) 3.0E-3 0.76 (0.56,1.03) 1.17 (1.01,1.35) 1.2E-2 1.9E-2
rs10867977 MYH9 1.7E-4 0.67 (0.54,0.83) 7.8E-1 1.03 (0.82,1.30) 1.2E-2 0.85 (0.64,1.13) 1.31 (1.06,1.62) 1.6E-2 2.2E-2
1,592 T2DM-ESRD Discovery and Replication cases versus 1,671 Discovery and Replication non-diabetic non-nephropathy (NDNN) controls (* Homogeneity P-Value
refers to the P-Value from the test for homogeneity of the odds ratio; ** Two-locus logistic regression interaction analysis).
doi:10.1371/journal.pgen.1002150.t004
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potentially interacting with the MYH9 E1 haplotype in DN
susceptibility, an effect replicated in additional AAs with T2DM-
ESRD. Our analyses in 3263 AA T2DM-ESRD cases and non-
diabetic, non-nephropathy controls revealed an approximate 25–
30% increase in DN risk with multiple FRMD3 SNPs in subjects
not homozygous for the MYH9 E1 risk haplotype (or APOL1 risk
variants). Interaction analyses between FRMD3 SNPs were
repeated in non-diabetic nephropathy cases (with biopsy-proven
FSGS and HIVAN) and interactions were not observed. This
suggests that the FRMD3 association is limited to DN. In
retrospect, the case-only interaction analyses based on MYH9
(and APOL1) risk variants likely segregated clinically diagnosed
cases of T2DM-ESRD into those enriched for non-diabetic
nephropathy (c22 nephropathy risk homozygotes with disease in
the FSGS spectrum) and non-c22 homozygotes enriched for true
DN. The discrepant effect of FRMD3 protection in c22
nephropathy homozygotes, versus risk in non-c22 nephropathy
homozygotes, raised the possibility that the T2DM-ESRD case
group contained subsets of cases with different diseases. We
suggest that these groups were not comparable based on c22 status
[12]. This partitioning allowed for detection of DN association
with FRMD3 SNPs, limited to the non-MYH9 E1 homozygotes.
The analyses were repeated with other SNPs in the complex and
extended LD region about the MYH9 E1 haplotype on c22,
including APOL1, with comparable directions of results and less
significant p-values.
Genetic heterogeneity and gene-gene or gene-environment
interactions are frequently hypothesized as being important in
complex genetic disorders such as nephropathy. It remains
uncommon to formally test and replicate interaction and multiple
loci models. We posit that some variant’s risk may depend on the
influences of other genes or non-genetic factors. Clearly, variants
with strong effects such as MYH9 and APOL1 are important in and
of themselves. However, an important lesson from the current
study is that since the MYH9 E1 haplotype is extremely common
in AAs and has a large odds ratio, the E1 haplotype may mask the
effects at other loci unless methods are used to account for its
influence (e.g., multilocus models, interaction analyses, stratifica-
tion analyses). We have no reason to expect different results in
European-derived populations since MYH9 risk variants are also
strongly associated with non-diabetic ESRD in Europeans and
European Americans; however, larger sample sizes would need to
be tested due to the markedly lower frequencies of APOL1 and
MYH9 risk variants.
The challenge of developing effective genetic screening tests is
the balance between correctly identifying those variants that
correctly and accurately predict individuals who will develop
disease and those who will not (i.e., balance between sensitivity
and specificity). Here, the MYH9 E1 haplotype was both an
important predictor and clarifier of the contribution of other loci
to the risk of nephropathy. Therefore, the search for additional
nephropathy susceptibility loci in AAs, conditional on other
important loci (MYH9 and APOL1) remains critical. It initially
appeared that variants in FRMD3 were protective and modified
risk for developing T2DM-ESRD in AAs with two MYH9 E1 risk
haplotypes; however, these same variants were associated with risk
for T2DM-ESRD in non-E1 haplotype homozygotes. This
observation suggested that the subset of ESRD cases homozygous
for the E1 haplotype differed from non-E1 homozygotes as to their
etiology of ESRD and is supported by the observation that biopsy-
proven FSGS can be present in AA with T2DM and heavy
proteinuria in individuals homozygous for the MYH9 E1 risk
haplotype [12]. Coding variants in APOL1 are major susceptibility
loci for non-diabetic nephropathy; however, independent, weaker
MYH9 effects remain plausible. This report demonstrates that the
FRMD3 association with DN was more readily detectable in non-
MYH9 risk homozygotes, relative to non-APOL1 risk homozygotes,
an observation that supports a potential independent role for
MYH9 in nephropathy susceptibility.
The strong association observed between variants in APOL1 and
near the MYH9 gene with several kidney diseases was a major
breakthrough in our understanding of nephropathy susceptibility
in AA [13,18]. Additional nephropathy susceptibility genes have
been identified using GWAS [16,17,19]. For example, the 4.1
protein ezrin, radixin, moesin [FERM] domain containing 3 locus
Table 5. Chromosome 22-FRMD3 interaction analysis.
T2DM-ESRD
Cases Only
T2DM Non-
Nephropathy
Controls Only
Cases vs.
Controls
c22 risk
homozygotes
Non-c22
Homozygotes
c22 risk homozygotes
vs.
non-risk
Marker
Gene
Interaction
P-Value
Additive OR (95% CI)
P-Value
Additive OR (95% CI)
Homogeneity
P-Value OR (95% CI) OR (95% CI)
Homogeneity
P-Value*
Classic
Logit P-
Value**
rs2378658 MYH9 9.5E-6 0.69 (0.59,0.82) 7.0E-1 0.94 (0.71,1.26) 5.6E-2 0.80 (0.61,1.05) 1.18 (0.97,1.44) 2.2E-2 2.5E-2
APOL1 4.5E-3 0.75 (0.61,0.91) 5.2E-1 1.12 (0.79,1.58) 3.8E-2 0.62 (0.38,1.01) 1.08 (0.88,1.32) 4.0E-2 1.5E-2
rs1535753 MYH9 1.7E-5 0.7 (0.60,0.82) 8.4E-1 0.97 (0.73,1.29) 4.4E-2 0.80 (0.61,1.04) 1.21 (1.00,1.48) 1.3E-2 1.4E-2
APOL1 6.0E-3 0.76 (0.62,0.92) 4.7E-1 1.14 (0.80,1.61) 2.3E-2 0.58 (0.35,0.96) 1.09 (0.89,1.33) 2.2E-2 9.9E-03
rs942283 MYH9 2.3E-6 0.68 (0.57,0.79) 5.9E-1 0.92 (0.69,1.23) 5.4E-2 0.78 (0.60,1.03) 1.18 (0.97,1.44) 1.6E-2 1.7E-2
APOL1 3.6E-3 0.74 (0.61,0.91) 6.6E-1 1.08 (0.76,1.53) 2.8E-2 0.58 (0.35,0.95) 1.08 (0.88,1.32) 2.4E-2 1.1E-2
rs942280 MYH9 9.3E-7 0.67 (0.57,0.78) 5.3E-1 0.91 (0.68,1.22) 5.1E-2 0.83 (0.63,1.08) 1.22 (1.00,1.49) 2.0E-2 2.3E-2
APOL1 1.2E-3 0.72 (0.59,0.88) 6.2E-1 1.09 (0.77,1.54) 1.5E-2 0.54 (0.33,0.91) 1.14 (0.93,1.39) 8.0E-3 3.4E-3
rs942278 MYH9 1.5E-5 0.7 (0.59,0.82) 9.6E-1 1.01 (0.75,1.34) 2.5E-2 0.82 (0.63,1.07) 1.26 (1.03,1.53) 1.1E-2 1.3E-2
APOL1 6.5E-3 0.76 (0.62,0.93) 6.3E-1 1.09 (0.77,1.54) 2.6E-2 0.60 (0.37,1.0) 1.15 (0.94,1.4) 1.8E-2 8.7E-3
1,592 Discovery and Replication T2DM-ESRD cases versus 513 T2DM non-nephropathy controls (* Homogeneity P-Value refers to the P-Value from the test for
homogeneity of the odds ratio; ** Two-locus logistic regression interaction analysis).
doi:10.1371/journal.pgen.1002150.t005
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diabetes (T1DM) in European Americans from the Genetics of
Kidneys in Diabetes (GoKinD) collection, with replication based
upon nephropathy progression rates in subjects with T1DM in the
Diabetes Control and Complications Trial (DCCT)/Epidemiology
of Diabetes Interventions and Complications (EDIC) Study [17].
Despite replication, the GoKinD GWAS failed to reach genome-
wide significant evidence of association. It was also unclear
whether FRMD3 was a susceptibility gene for only T1DM-
associated nephropathy or contributed to other etiologies of kidney
disease. FRMD3 variants now appear to impact susceptibility to
nephropathy from T1DM and T2DM with effects in European-
and African-derived populations, apparently not in Japanese [20].
FRMD3 is expressed in human kidney [17]. The expression
profile of FRMD3 includes human renal mesangial and proximal
tubular cells, but has not yet been tested in podocytes [17,21].
FERM domains are present in a variety of mammalian proteins
and the functions of FERM domain-containing proteins, although
not completely known, imply that these domains link the plasma
membrane with cytoskeletal structures at specific cellular locations
by directly binding partner proteins and/or phosphoinositides
[22]. FRMD3 encodes a protein with unknown function [23];
although other 4.1 protein family members are important in
maintenance of cell shape [24] and may maintain cell integrity by
interacting with transmembrane proteins and actin filaments
[25,26]. Human FERM domain-containing proteins include
kinases (focal adhesion kinase [FAK] and Janus kinases [JAKs]),
myosins (MYO7, MYO10 and MYO15), phosphatases (protein-
tyrosine phosphatase 1E [PTPE1]), ERMs, kindlins, talins, and
other less well-characterized proteins. Although FERM-domain
containing proteins interact with myosins, we do not feel that our
genetic results support FRMD3 and MYH9 variants directly
interacting to initiate diabetic nephropathy in African Americans.
Instead, cases with clinically-diagnosed T2DM-ESRD possessing
two copies of the MYH9 E1 risk haplotype more likely had non-
diabetic forms of ESRD (in the FSGS family and mis-diagnosed as
T2DM-ESRD). When limiting analyses to non-MYH9 risk
homozygotes, thereby enriching for T2DM-ESRD, the FRMD3
genetic association became evident. The FRMD3 SNPs that were
associated with T1DM-associated nephropathy in GoKinD
samples were subsequently tested in our AA T2DM-ESRD cases
and non-diabetic, non-nephropathy controls. These SNPs are not
in LD with the 7 SNPs identified in this report (r
2=0.01–0.03 in
both Yorubans and CEU). No evidence of association of the
GoKinD associated FRMD3 SNPs was seen in our AA sample with
T2DM-ESRD (data not shown).
A limitation of this report was use of a non-diabetic non-
nephropathy control group with younger ages and absence of
detailed renal phenotyping, relative to T2DM-ESRD cases.
Although occult nephropathy in controls would reduce power to
detect association, survival-bias could result. Replication in the
T2DM non-nephropathy controls likely reduced (but does not
eliminate) the potential for survival bias. Similarly, it is difficult to
recruit large numbers of AA controls with longstanding T2DM
who lack kidney disease, due to the high prevalence of subclinical
nephropathy in AAs with diabetes mellitus.
We conclude that variants in FRMD3 contribute to the risk for
nephropathy in AA with T2DM, an effect that was observed only
after accounting for MYH9 (and less so APOL1) gene variants and
evaluating a subset of AA cases likely enriched for T2DM-
associated nephropathy. These analyses replicate the FRMD3
association in susceptibility to DN, as well as implicate this gene in
African-derived populations. In addition to the nephropathy risk
imparted by APOL1 G1 and G2 variants, our results support
residual nephropathy risk residing within MYH9, or other c22
variants in linkage disequilibrium with the MYH9 E1 haplotype.
Materials and Methods
Patient populations
Diagnostic criteria for T2DM-associated ESRD in Wake Forest
University School of Medicine (WFUSM) participants (both
discovery and replication samples) includes diabetes diagnosis at
age .30 years (in the absence of diabetic ketoacidosis); with either
renal histologic evidence of DN or diabetes duration $5 years
before initiation of renal replacement therapy in the presence of
diabetic retinopathy or proteinuria $500 mg/24 h and absence of
other known causes of nephropathy [3,15]. Non-diabetic, non-
nephropathy controls were recruited to be at low risk for
nephropathy based upon the lack of a personal or family history
of kidney disease; therefore, renal function testing is not routinely
performed due to the low yield of nephropathy. In a subset of 200
non-diabetic, non-nephropathy controls, 98% (196/200) had
serum creatinine concentrations ,1.5 mg/dl (maximum
1.85 mg/dl). We note that occult kidney disease in non-diabetic,
non-nephropathy controls would bias against association and
deflate significance. T2DM non-nephropathy controls met criteria
for diabetes and had an estimated glomerular filtration rate
.60 ml/min and spot albumin:creatinine ratio ,100 mg/g.
Among T2DM non-nephropathy controls, 67.5% had diabetes
durations exceeding 5 years and 29.6% reported diabetic
retinopathy, 57.5% denied retinopathy; and 12.9% were unsure.
All subjects provided written informed consent and studies were
approved by the WFUSM Institutional Review Board and adhere
to the tenets of the Declaration of Helsinki. Clinical criteria for
National Institute of Health (NIH) biopsy-proven FSGS cases (229
with idiopathic FSGS; 54 with HIVAN collapsing glomerulopa-
thy) and 222 controls have also been reported [1].
Genotyping and quality control
Genotyping of the Affymetrix Genome-Wide Human SNP
Array 6.0 in the discovery sample of 966 AA cases with T2DM-
ESRD and 1032 non-diabetic, non-nephropathy controls was
completed at the Center for Inherited Disease Research (CIDR;
www.cidr.jhmi.edu) using DNA extracted from peripheral blood.
DNA from cases and controls were approximately balanced on
each 96-well master plate. A fingerprinting set of 96 SNPs was
independently genotyped in all samples and results compared to
the corresponding SNPs on the Affymetrix array to confirm
sample identity. Genotypes were called using Birdseed version 2;
APT 1.10.0 by grouping samples by DNA plate to determine the
genotype cluster boundaries. The minimum SNP call rate for an
individual was 98.4%. Forty-six blind duplicates were genotyped
and had a concordance rate of 99.59%. Cryptic relatedness was
identified by the estimated identity-by-descent (IBD) statistics as
implemented in PLINK (http://pngu.mgh.harvard.edu/purcell/
plink/). There were two unexpected duplicate pairs and 54
unexpected first-degree relative pairs. One of each of these pairs
was removed by the following rules: 1) retain T2DM-ESRD cases
over non-diabetic, non-nephropathy controls, and 2) if case/
control status was congruent, retain the individual with the most
complete phenotype data. One individual had a self-reported
gender inconsistent with X chromosome genotype data and one
had an inbreeding coefficient, F-statistic, more than 4 standard
deviations from the mean, both were excluded. The results are
based on the remaining 952 T2DM-ESRD cases and 988 non-
diabetic, non-nephropathy controls. Replication samples were
recruited under identical ascertainment criteria to the discovery
FRMD3 and Diabetic Nephropathy
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TM
Sequenom MassARRAY platform for replication. Genotyping
efficiency .95% and 45 blind duplicates were included to ensure
genotyping accuracy. Genotyping FSGS and HIVAN cases and
controls were by TaqMan assays available from ABI Biosystems
(Foster City, CA).
Statistical analysis
Each SNP was tested for departure from Hardy-Weinberg
Equilibrium (HWE) expectations using a chi square goodness-of-fit
test. The primary inference for this conditional/interaction
GWAS was the SNPs with ,5% missing and no differential
missingness between cases and controls, HWE p-value.1E
24 in
cases and .1E
22 in controls and minor allele frequency (MAF) in
the entire sample .0.05. A total of 832,357 SNPs met these
criteria. However, SNPs that did not meet these criteria were
secondarily examined for association with consideration given to
potential corroborating evidence of association at flanking SNPs,
especially those SNPs with some evidence of HWE departure. The
average sample call rate was 99.16% for all autosomal SNPs.
A principal components analysis (PCA) was computed on the
832,357 SNPs to estimate the primary sources of genetic
variations, including potential admixture. One principal compo-
nent (PC) was retained and it correlated highly (r
2=0.87) with
previously computed admixture estimates based on 70 ancestry
informative markers (AIMs) using the program FRAPPE [27]. The
same set of AIMs was genotyped in the replication sample and
admixture estimates were computed using FRAPPE. As described
below, the GWAS association analyses adjust for the first PC and
the replication study and combined analyses adjusted for
admixture estimates.
Since not all individuals homozygous for APOL1 risk variants
and/or the MYH9 E1 risk haplotype develop nephropathy, the
probability of developing ESRD may depend on non-genetic
factors and other genetic factors interacting with the known c22
risk variants. Thus, a series of complementary logistic regression
analyses were computed using the program SNPGWA (www.phs.
wfubmc.edu). The analyses were restricted to SNPs with minor
allele frequencies .0.10. The primary inference for the following
analyses used the additive genetic model for the SNP, provided
there was no evidence of departure from the additive genetic
model (additive model lack-of-fit test p-value.5E
22). If the lack-
of-fit to an additive model was significant, then the minimum of
the dominant, additive and recessive model is reported. In
addition, additive genetic models required at least ten individuals
homozygous for the minor allele and recessive models required at
least 30 individuals homozygous for the minor allele.
The primary analysis consisted of a case-only test for an
interaction between homozygosity for the MYH9 E1 haplotype or
APOL1 risk variants (G1/G1; G2/G2; G1/G2) and individual
SNPs across the genome. Specifically, a logistic regression model
was computed in cases where the binary outcome was homozy-
gosity for APOL1 risk SNPs or MYH9 E1 haplotypes (versus not
homozygous) and independent variables (covariates) were age,
gender, first PC to account for admixture and SNP. The case-only
analysis makes the strong assumption that the SNP being tested
and homozygosity for the c22 variants are independent under the
null hypothesis of no interaction. If the assumption of indepen-
dence under the null hypothesis is met, this case-only analysis can
have considerably more statistical power than the corresponding
classic case-control interaction model [28]. To make the inference
as robust to this assumption as possible, the test was restricted to
those SNPs not on c22; note by Mendel’s Law of Independent
Assortment chromosomes are inherited independently and
therefore the independence assumption is met. This assumption
was further examined by testing for the interaction in the control
sample.
As an aid to interpret the case-only interaction analysis, the
corresponding classic two-locus logistic regression interaction
model was computed. Here, the logistic regression model had
T2DM-ESRD status as the outcome, and the predictor variables
(covariates) of age, gender, PC, the SNP, an indicator variable for
two APOL1 risk variants or MYH9 E1 haplotype homozygosity and
the centered cross-product of the SNP and indicator for c22 risk
variant homozygosity. Here we mean the standard logistic
regression model for two predictor variables (say X1 and X2) with
their interaction term, a centered cross-product (e.g., Z) to reduce
collinearity/correlation among the variables. Specifically, we
would write this model as: logit y ðÞ ~b0zb1X1zb2X2zb3Z;
where, X1 is the SNP and X2 is the indicator variable for the
APOL1/MYH9 haplotype (see below), respectively and Z is the
center cross-product defined as Z~ X1{ X X1 ðÞ X2{ X X2 ðÞ . The
variable Z is defined in this way to reduce the collinearity or
correlation among the predictors for better estimation properties.
The indicator variable is a binary variable that codes an individual
as either 0 or 1, depending on the characteristic of interest. Here,
the indicator variable was 1 if the person was homozygous for the
APOL1/MYH9 haplotype (easily determinable as it is a recessive
model and phase is unambiguous) and 0 if they were not
homozygous for these risk haplotypes. This binary (0, 1) variable
was included in the logistic regression model. For the case-only
analysis, this indicator variable was the outcome in the logistic
regression analysis and for the classic two-locus interaction logistic
regression models it was one of the predictor variables.
Subsequent analyses stratified by homozygosity at the MYH9 E1
haplotype and APOL1 risk variants. A logistic regression model was
computed in individuals homozygous for c22 variants, where
T2DM-ESRD status was the outcome and the independent
variables (covariates) in the model included age, gender, the first
PC and the SNP of interest. The analysis was repeated for
individuals not homozygous for c22 variants and the test for
homogeneity of the odds ratio was computed. Analyses in the
replication cohorts paralleled those in the discovery cohort.
To determine whether associated SNPs from analyses contrast-
ing individuals with T2DM-ESRD to those without diabetes were
DN-associated or T2DM-associated, allele frequencies were
compared between AA with T2DM lacking nephropathy to those
in the combined T2DM-ESRD case groups and the combined
non-diabetic, non-nephropathy control groups.
Assuming a recessive model for the MYH9 and APOL1 risk
variants with main effect OR=1.5, haplotype frequency of 0.64,
and an additive genetic model for the FRMD3 SNPs having no
main effect (OR=1.0) with minor allele frequency of 0.32, then
with a type 1 error rate of a=1
210, we have 0.50 power to detect
an OR=2.05 and 0.80 power to detect an OR=2.34.
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